Literature DB >> 20425561

Deconstructing most recent antiretroviral recommendations.

David Alain Wohl1.   

Abstract

The selection of antiretroviral therapy for HIV-infected persons initiating treatment is influenced by numerous factors, including efficacy, safety, convenience, drug interactions, and cost, among others. Guidelines have been developed to assist the clinician in choosing regimens that have been found to be effective in clinical studies. Understanding the recommendations of the major US treatment guideline for initial HIV therapy is essential for clinicians caring for such patients.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20425561     DOI： 10.1007/s11904-010-0040-x

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN： 1548-3568            Impact factor:   5.071


  11 in total

1.  The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.

Authors:  Joseph Eron; Patrick Yeni; Joseph Gathe; Vicente Estrada; Edwin DeJesus; Schlomo Staszewski; Philip Lackey; Christine Katlama; Benjamin Young; Linda Yau; Denise Sutherland-Phillips; Paul Wannamaker; Cindy Vavro; Lisa Patel; Jane Yeo; Mark Shaefer
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

2.  Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

Authors:  Sharon Walmsley; Anchalee Avihingsanon; Jihad Slim; Douglas J Ward; Kiat Ruxrungtham; Jason Brunetta; U Fritz Bredeek; Dushyantha Jayaweera; Carol Jean Guittari; Peter Larson; Malte Schutz; François Raffi
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-01       Impact factor: 3.731

3.  Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.

Authors:  Cindy H Brothers; Jaime E Hernandez; Amy G Cutrell; Lloyd Curtis; Mounir Ait-Khaled; Steve J Bowlin; Sara H Hughes; Jane M Yeo; Didier H Lapierre
Journal:  J Acquir Immune Defic Syndr       Date:  2009-05-01       Impact factor: 3.731

4.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.

Authors:  F van Leth; P Phanuphak; K Ruxrungtham; E Baraldi; S Miller; B Gazzard; P Cahn; U G Lalloo; I P van der Westhuizen; D R Malan; M A Johnson; B R Santos; F Mulcahy; R Wood; G C Levi; G Reboredo; K Squires; I Cassetti; D Petit; F Raffi; C Katlama; R L Murphy; A Horban; J P Dam; E Hassink; R van Leeuwen; P Robinson; F W Wit; J M A Lange
Journal:  Lancet       Date:  2004-04-17       Impact factor: 79.321

5.  Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Authors:  Roberto Ortiz; Edwin Dejesus; Homayoon Khanlou; Evgeniy Voronin; Jan van Lunzen; Jaime Andrade-Villanueva; Jan Fourie; Sandra De Meyer; Martine De Pauw; Eric Lefebvre; Tony Vangeneugden; Sabrina Spinosa-Guzman
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

6.  Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Authors:  Anthony M Mills; Mark Nelson; Dushyantha Jayaweera; Kiat Ruxrungtham; Isabel Cassetti; Pierre-Marie Girard; Cassy Workman; Inge Dierynck; Vanitha Sekar; Carline Vanden Abeele; Ludo Lavreys
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

7.  A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

Authors:  Michael Saag; James Goodrich; Gerd Fätkenheuer; Bonaventura Clotet; Nathan Clumeck; John Sullivan; Mike Westby; Elna van der Ryst; Howard Mayer
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

8.  Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

Authors:  Jose R Arribas; Anton L Pozniak; Joel E Gallant; Edwin Dejesus; Brian Gazzard; Rafael E Campo; Shan-Shan Chen; Damian McColl; Charles B Holmes; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Journal:  J Acquir Immune Defic Syndr       Date:  2008-01-01       Impact factor: 3.731

9.  Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Authors:  Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetchotisakd; Jorge Corral; Neal David; Graeme Moyle; Marco Mancini; Lisa Percival; Rong Yang; Alexandra Thiry; Donnie McGrath
Journal:  Lancet       Date:  2008-08-23       Impact factor: 79.321

10.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Authors:  Kimberly Y Smith; Parul Patel; Derek Fine; Nicholaos Bellos; Louis Sloan; Philip Lackey; Princy N Kumar; Denise H Sutherland-Phillips; Cindy Vavro; Linda Yau; Paul Wannamaker; Mark S Shaefer
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177
View more
  1 in total

Review 1.  Nanomedicine as an emerging approach against intracellular pathogens.

Authors:  Andrea L Armstead; Bingyun Li
Journal:  Int J Nanomedicine       Date:  2011-12-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.